Pharmacologic treatment of lower urinary tract dysfunction in the female patient.
As a result of the renewed interest in the neuropharmacology and neurophysiology of the urinary bladder and its outlet, pharmacologic therapy now exists that is helpful in the management of many types of voiding dysfunctions. This article summarizes the pharmacologic principles upon which this drug therapy is based and shows how pharmacologic treatment fits into a functional scheme of therapy for disorders of micturition, here specifically related to the female patient with lower urinary tract dysfunction.
Wein
A J
AJ
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D018723:Bethanechol; D001626:Bethanechol Compounds / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D009125:Muscle Relaxants, Central / Q000494:pharmacology / Q000627:therapeutic use; D009130:Muscle, Smooth / Q000187:drug effects; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011941:Receptors, Adrenergic / Q000502:physiology; D014521:Urethra / Q000187:drug effects / Q000294:innervation; D001743:Urinary Bladder / Q000187:drug effects / Q000294:innervation; D001745:Urinary Bladder Diseases / Q000188:drug therapy; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy; D014555:Urination Disorders / Q000188:drug therapy; D014570:Urologic Diseases / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000929:Antidepressive Agents, Tricyclic; D001626:Bethanechol Compounds; D009125:Muscle Relaxants, Central; D010276:Parasympatholytics; D011941:Receptors, Adrenergic; D018723:Bethanechol; D010643:Phenoxybenzamine; D007099:Imipramine; D011224:Prazosin